Abbott Laboratories
ABT133.550USD
+0.250+0.19%
Close 09/26, 16:00（ET）Quotes delayed by 15 min
232.44BMarket Cap
16.63P/E TTM
More Details of Abbott Laboratories Company
Abbott Laboratories is an American multinational health care and medical devices corporation headquartered in Abbott Park, Illinois. Founded in 1888 by Chicago physician Wallace Calvin Abbott, the company initially focused on formulating known drugs. Today, it offers medical devices, diagnostics, branded generic medications, and nutritional products. In 2013, Abbott separated its research-based pharmaceuticals division into AbbVie.
Abbott's product lineup includes Pedialyte, Similac, BinaxNOW, Ensure, Glucerna, ZonePerfect, FreeStyle Libre, i-STAT, and MitraClip.
Company Info
Ticker SymbolABT
Company nameAbbott Laboratories
IPO dateMar 01, 1937
CEOMr. Robert B. Ford
Number of employees114000
Security typeOrdinary Share
Fiscal year-endMar 01
Address100 Abbott Park Road
CityABBOTT PARK
Stock exchangeNYSE Consolidated
CountryUnited States of America
Postal code60064-3500
Phone12246676100
Websitehttps://www.abbott.com
Ticker SymbolABT
IPO dateMar 01, 1937
CEOMr. Robert B. Ford
Company Executives
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Mr. Philip P. Boudreau
Mr. Philip P. Boudreau
Chief Financial Officer, Executive Vice President - Finance
Chief Financial Officer, Executive Vice President - Finance
50.97K
-0.75%
Dr. Robert J. Alpern, M.D.
Dr. Robert J. Alpern, M.D.
Independent Director
Independent Director
40.80K
+4.17%
Ms. Nancy Mckinstry
Ms. Nancy Mckinstry
Lead Independent Director
Lead Independent Director
38.72K
+4.41%
Ms. Sally E. Blount, Ph.D.
Ms. Sally E. Blount, Ph.D.
Independent Director
Independent Director
34.06K
-2.76%
View more
Name
Name/Position
Position
Shareholding
Change
Mr. Daniel J. Starks
Mr. Daniel J. Starks
Independent Director
Independent Director
6.73M
+0.02%
Mr. Hubert L. Allen
Mr. Hubert L. Allen
Executive Vice President, General Counsel, Secretary
Executive Vice President, General Counsel, Secretary
191.90K
+3.84%
Mr. Daniel Gesua Sive Salvadori
Mr. Daniel Gesua Sive Salvadori
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
Executive Vice President, Group President - Established Pharmaceuticals and Nutritional Products
133.77K
+6.42%
Ms. Mary K. Moreland
Ms. Mary K. Moreland
Executive Vice President - Human Resources
Executive Vice President - Human Resources
95.58K
-0.82%
Ms. Lisa D. Earnhardt
Ms. Lisa D. Earnhardt
Executive Vice President, Group President - Medical Devices
Executive Vice President, Group President - Medical Devices
71.93K
--
Mr. Louis H. (Lou) Morrone
Mr. Louis H. (Lou) Morrone
Executive Vice President - Core Diagnostics
Executive Vice President - Core Diagnostics
66.61K
-0.40%
Revenue Breakdown
Currency: USDUpdated: Sun, Jul 6
Currency: USDUpdated: Sun, Jul 6
FY2025Q1
FY2024
FY2024Q4
FY2024Q3
FY2024Q2
FY2024Q1
FY2023
FY2023Q4
FY2023Q3
FY2023Q2
FY2023Q1
FY2022
FY2022Q4
FY2022Q3
FY2022Q2
FY2022Q1
FY2021
FY2020
FY2019
By BusinessUSD
Name
Revenue
Proportion
Diabetes Care
1.83B
17.64%
Core Laboratory
1.18B
11.36%
Adult Nutritionals
1.10B
10.67%
Pediatric Nutritionals
1.04B
10.05%
Key Emerging Markets
965.00M
9.32%
Other
4.24B
40.96%
By RegionUSD
Name
Revenue
Proportion
All other Countries
6.19B
59.76%
United States
4.17B
40.24%
By Business
By Region
By BusinessUSD
Name
Revenue
Proportion
Diabetes Care
1.83B
17.64%
Core Laboratory
1.18B
11.36%
Adult Nutritionals
1.10B
10.67%
Pediatric Nutritionals
1.04B
10.05%
Key Emerging Markets
965.00M
9.32%
Other
4.24B
40.96%
Shareholding Stats
Updated: Fri, Aug 15
Updated: Fri, Aug 15
Shareholders
Shareholder Types
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Global Advisors (US)
4.50%
Capital International Investors
3.46%
Capital Research Global Investors
2.40%
Other
74.67%
Shareholders
Shareholders
Proportion
The Vanguard Group, Inc.
9.88%
BlackRock Institutional Trust Company, N.A.
5.09%
State Street Global Advisors (US)
4.50%
Capital International Investors
3.46%
Capital Research Global Investors
2.40%
Other
74.67%
Shareholder Types
Shareholders
Proportion
Investment Advisor
46.40%
Investment Advisor/Hedge Fund
23.17%
Research Firm
3.60%
Bank and Trust
2.24%
Pension Fund
2.21%
Sovereign Wealth Fund
1.37%
Insurance Company
1.06%
Individual Investor
0.48%
Hedge Fund
0.44%
Other
19.02%
Institutional Shareholding
Updated: Tue, Jul 1
Updated: Tue, Jul 1
Reporting Period
No. of institutions
Shares Held
Proportion
Change
2025Q2
4616
1.41B
81.28%
+6.94M
2025Q1
4644
1.42B
81.42%
+12.91M
2024Q4
4535
1.39B
80.22%
+15.89M
2024Q3
4391
1.36B
78.29%
-11.85M
2024Q2
4400
1.36B
78.24%
-7.03M
2024Q1
4402
1.35B
77.67%
-9.71M
2023Q4
4429
1.35B
77.56%
-11.05M
2023Q3
4298
1.34B
77.39%
-25.33M
2023Q2
4297
1.35B
77.60%
-13.55M
2023Q1
4281
1.35B
77.46%
-8.61M
View more
Shareholder Activity
Name
Shares Held
Proportion
Change
Chg %
Date
The Vanguard Group, Inc.
169.07M
9.72%
+1.18M
+0.70%
Mar 31, 2025
BlackRock Institutional Trust Company, N.A.
87.82M
5.05%
+752.19K
+0.86%
Mar 31, 2025
State Street Global Advisors (US)
77.66M
4.46%
+497.07K
+0.64%
Mar 31, 2025
Capital International Investors
66.82M
3.84%
-1.15M
-1.69%
Mar 31, 2025
Capital Research Global Investors
50.73M
2.92%
-3.36M
-6.22%
Mar 31, 2025
Geode Capital Management, L.L.C.
36.90M
2.12%
+1.23M
+3.46%
Mar 31, 2025
JP Morgan Asset Management
28.80M
1.66%
+3.67M
+14.58%
Mar 31, 2025
Wellington Management Company, LLP
29.76M
1.71%
+3.37M
+12.77%
Mar 31, 2025
Norges Bank Investment Management (NBIM)
20.98M
1.21%
+626.72K
+3.08%
Dec 31, 2024
Wells Fargo Advisors
15.42M
0.89%
+165.54K
+1.09%
Mar 31, 2025
View more
Related ETFs
Updated: Tue, Sep 2
Updated: Tue, Sep 2
Name
Proportion
iShares U.S. Medical Devices ETF
16.79%
Goldman Sachs Future Health Care Equity ETF
6.3%
GMO US Quality ETF
5.19%
Invesco Pharmaceuticals ETF
4.64%
Polen Capital Global Growth ETF
4.64%
iShares U.S. Healthcare ETF
4.45%
Proshares Ultra Health Care
4.45%
Health Care Select Sector SPDR Fund
4.38%
AdvisorShares Focused Equity ETF
4.37%
Tema Heart & Health ETF
4.31%
View more
iShares U.S. Medical Devices ETF
Proportion16.79%
Goldman Sachs Future Health Care Equity ETF
Proportion6.3%
GMO US Quality ETF
Proportion5.19%
Invesco Pharmaceuticals ETF
Proportion4.64%
Polen Capital Global Growth ETF
Proportion4.64%
iShares U.S. Healthcare ETF
Proportion4.45%
Proshares Ultra Health Care
Proportion4.45%
Health Care Select Sector SPDR Fund
Proportion4.38%
AdvisorShares Focused Equity ETF
Proportion4.37%
Tema Heart & Health ETF
Proportion4.31%
Dividend
A total of
16.46B
USD has been distributed in dividends over the past 5 years.
Date
Dividend
Record Date
Payment Date
Ex-dividend Date
Dec 13, 2024
ABT.NB Interim Cash Dividend of gross USD 0.59 paid on Feb 14, 2025 going ex on Jan 15, 2025 with reinvestment option
Jan 15, 2025
Feb 14, 2025
Jan 15, 2025
Sep 19, 2024
ABT.NB Final Cash Dividend of gross USD 0.55 paid on Nov 15, 2024 going ex on Oct 15, 2024
Oct 15, 2024
Nov 15, 2024
Oct 15, 2024
Jun 15, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Aug 15, 2024 going ex on Jul 15, 2024 with reinvestment option
Jul 15, 2024
Aug 15, 2024
Jul 15, 2024
Feb 16, 2024
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on May 15, 2024 going ex on Apr 12, 2024
Apr 15, 2024
May 15, 2024
Apr 12, 2024
Dec 15, 2023
ABT.NB Interim Cash Dividend of gross USD 0.55 paid on Feb 15, 2024 going ex on Jan 11, 2024 with reinvestment option
Jan 12, 2024
Feb 15, 2024
Jan 11, 2024
Sep 21, 2023
ABT.NB Final Cash Dividend of gross USD 0.51 paid on Nov 15, 2023 going ex on Oct 12, 2023 with reinvestment option
Oct 13, 2023
Nov 15, 2023
Oct 12, 2023
Jun 09, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Aug 15, 2023 going ex on Jul 13, 2023 with reinvestment option
Jul 14, 2023
Aug 15, 2023
Jul 13, 2023
Feb 17, 2023
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on May 15, 2023 going ex on Apr 13, 2023 with reinvestment option
Apr 14, 2023
May 15, 2023
Apr 13, 2023
Dec 09, 2022
ABT.NB Interim Cash Dividend of gross USD 0.51 paid on Feb 15, 2023 going ex on Jan 12, 2023 with reinvestment option
Jan 13, 2023
Feb 15, 2023
Jan 12, 2023
Sep 15, 2022
ABT.NB Final Cash Dividend of gross USD 0.47 paid on Nov 15, 2022 going ex on Oct 13, 2022 with reinvestment option
Oct 14, 2022
Nov 15, 2022
Oct 13, 2022
View more
Stock Split
Date
Type
Ratio
No Data
Date
Type
Ratio
No Data
